Program
In-person AND virtual! – We are pioneering a new conference format that will connect in-person and virtual audiences to create a unique experience. Matching the innovation that comes through our members’ work, ISPOR is pushing the boundaries
of innovation to design an event that works in today’s quickly changing environment.
In-person registration included the full virtual experience, and virtual-only attendees will be able to tune into live in-person sessions and/or
watch captured in-person sessions on-demand in addition to having a variety of virtual-only sessions to attend.
Item Response Theory Analysis of the Ilqi
Speaker(s)
Griffiths P1, Grant L1, Arenson E2, Maheshwari V3, Viana R4
1Adelphi Values Ltd, Bollington, Cheshire, UK, 2Adelphi Values LLC, Boston, MA, USA, 3Novartis Healthcare Pvt. Ltd., Hyderabad, AP, India, 4Novartis Pharma AG, Basel, Switzerland
Presentation Documents
OBJECTIVES: The Immune Thrombocytopaenia (ITP) Life Quality Index (ILQI) is 10-item patient reported outcome (PRO) used in clinical practice to measure the impact of ITP. It was administered as part of the ITP World Impact Survey (I-WISh), a global observational study. This abstract summarizes the results of an Item Response Theory (IRT) analysis of the ILQI.
METHODS: IRT is a family of statistical models providing information about the performance of items and the scales they comprise through analysis of item responses. Two IRT models were considered. First the sample was treated as a single-group and a graded response model (≥3 response choices for each item within the PRO), the latter was employed to calibrate item discrimination and impact response thresholds. Secondly, to access the severity of impacts in patients in various countries, multiple-group one-parameter IRT models were assessed. All countries were compared to the USA, the largest cohort in the study.
RESULTS: Single-group IRT results indicated that all items had good discrimination (slopes≥1.96) and response thresholds covered a wide range of the underlying latent scale (between -2.39 and 6.70 logits), showing that the ILQI can measure a range of disease impacts with good precision. In the multi-group IRT model, statistically significant country-level effects were found compared to the USA. Of these, patients in Canada, China, Columbia, and Turkey had lower impacts than the USA, and patients in Japan and the UK had higher impacts.
CONCLUSIONS: Results support that the ILQI can measure a range of disease impacts. The single-group model assessing item discrimination showed that items could differentiate between patients with higher and lower disease impact. The multi-group IRT model detected some country-level differences in patient’s responses. This does not preclude the use of ILQI in non-USA countries, but suggests that patient report of disease impacts may vary between countries.
Code
PCR101
Topic
Clinical Outcomes, Methodological & Statistical Research, Patient-Centered Research
Topic Subcategory
Clinical Outcomes Assessment, Instrument Development, Validation, & Translation, Patient-reported Outcomes & Quality of Life Outcomes, PRO & Related Methods
Disease
Systemic Disorders/Conditions